Use of riluzole oral disintegrating tablets for treating diseases
Disclosed are methods of treating a disease in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of riluzole, or a pharmaceutically acceptable salt thereof, in the form of an oral solid molded fast-dispersing dosage form. Pharmaceutical compositions and kits are also disclosed.
1. A method of treating cerebellar ataxia in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising 50-70% riluzole, 15-25 weight % gelatin, 10-20 weight % mannitol, and 0.1-2 weight % docusate sodium, based on the total weight of the pharmaceutical composition, in the form of an oral solid molded fast-dispersing dosage form in order to provide an AUC 0-t of from about 80-125% of about 740000 hr*pg/mL, wherein the dosage of riluzole in the oral solid molded fast dispersing tablet is from 50 to 90% of the dosage of riluzole in a conventional tablet in order to provide an AUC 0-t of about 740000 hr*pg/mL.
2. The method of claim 1 , wherein the dosage of riluzole in the oral solid molded fast dispersing tablet is from 70 to 85% of the dosage of riluzole in a conventional tablet in order to provide an AUC 0-t of about 740000 hr*pg/mL.
3. The method of claim 2 , wherein the dosage of riluzole in the oral solid molded fast dispersing tablet is about 80% of the dosage of riluzole in a conventional tablet in order to provide an AUC 0-t of about 740000 hr*pg/mL.
4. The method of claim 1 , wherein the dosage of riluzole in the oral solid molded fast dispersing tablet is about 40 mg.